
Protein Analysis using Mass Spectrometry
Description
Alles über E-Books | Antworten auf Fragen rund um E-Books, Kopierschutz und Dateiformate finden Sie in unserem Info- & Hilfebereich.
More details
Other editions
Additional editions


Persons
Content
List of Contributors xiii
Foreword xvii
Preface xix
1 Contemporary Protein Analysis by Ion Mobility Mass Spectrometry 1
Johannes P.C. Vissers and James I. Langridge
1.1 Introduction 1
1.2 Traveling-Wave Ion Mobility Mass Spectrometry 1
1.3 IM-MS and LC-IM-MS Analysis of Simple and Complex Mixtures 2
1.4 Outlook 7
Acknowledgment 8
References 8
2 High-Resolution Accurate Mass Orbitrap and Its Application in Protein Therapeutics Bioanalysis 11
Hongxia Wang and Patrick Bennett
2.1 Introduction 11
2.2 Triple Quadrupole Mass Spectrometer and Its Challenges 11
2.3 High-Resolution Mass Spectrometers 12
2.4 Quantitation Modes on Q Exactive Hybrid Quadrupole Orbitrap 13
2.5 Protein Quantitation Approaches Using Q Exactive Hybrid Quadrupole Orbitrap 14
2.6 Data Processing 16
2.7 Other Factors That Impact LC-MS-based Quantitation 16
2.8 Conclusion and Perspectives of LC-HRMS in Regulated Bioanalysis 18
References 18
3 Current Methods for the Characterization of Posttranslational Modifications in Therapeutic Proteins Using Orbitrap Mass Spectrometry 21
Zhiqi Hao, Qiuting Hong, Fan Zhang, Shiaw-Lin Wu, and Patrick Bennett
3.1 Introduction 21
3.2 Characterization of PTMs Using Higher-Energy Collision Dissociation 23
3.3 Application of Electron Transfer Dissociation to the Characterization of Labile PTMs 26
3.4 Conclusion 31
Acknowledgment 32
References 32
4 Macro- to Micromolecular Quantitation of Proteins and Peptides by Mass Spectrometry 35
Suma Ramagiri, Brigitte Simons, and Laura Baker
4.1 Introduction 35
4.2 Key Challenges of Peptide Bioanalysis 36
4.3 Key Features of LC/MS/MS-Based Peptide Quantitation 38
4.4 Advantages of the Diversity of Mass Spectrometry Systems 41
4.5 Perspectives for the Future 41
References 42
5 Peptide and Protein Bioanalysis Using Integrated Column-to-Source Technology for High-Flow Nanospray 45
Shane R. Needham and Gary A. Valaskovic
5.1 Introduction - LC-MS Has Enabled the Field of Protein Biomarker Discovery 45
5.2 Integration of Miniaturized LC with Nanospray ESI-MS Is a Key for Success 46
5.3 Micro- and Nano-LC Are Well Suited for Quantitative Bioanalysis 47
5.4 Demonstrating Packed-Emitter Columns Are Suitable for Bioanalysis 49
5.5 Future Outlook 51
References 52
6 Targeting the Right Protein Isoform: Mass Spectrometry-Based Proteomic Characterization of Alternative Splice Variants 55
Jiang Wu
6.1 Introduction 55
6.2 Alternative Splicing and Human Diseases 55
6.3 Identification of Splice Variant Proteins 56
6.4 Conclusion 64
References 64
7 The Application of Immunoaffinity-Based Mass Spectrometry to Characterize Protein Biomarkers and Biotherapeutics 67
Bradley L. Ackermann and Michael J. Berna
7.1 Introduction 67
7.2 Overview of IA-MS Methods 69
7.3 IA-MS Applications - Biomarkers 74
7.3.1 Peptide Biomarkers 74
7.4 IA-MS Applications - Biotherapeutics 81
7.5 Future Direction 84
References 85
8 Semiquantification and Isotyping of Antidrug Antibodies by Immunocapture-LC/MS for Immunogenicity Assessment 91
Jianing Zeng, Hao Jiang, and Linlin Luo
8.1 Introduction 91
8.2 Multiplexing Direct Measurement of ADAs by Immunocapture-LC/MS for Immunogenicity Screening, Titering, and Isotyping 93
8.3 Indirect Measurement of ADAs by Quantifying ADA Binding Components 95
8.4 Use of LC-MS to Assist in Method Development of Cell-Based Neutralizing Antibody Assays 96
8.5 Conclusion and Future Perspectives 97
References 97
9 Mass Spectrometry-Based Assay for High-Throughput and High-Sensitivity Biomarker Verification 99
Xuejiang Guo and Keqi Tang
9.1 Background 99
9.2 Sample Processing Strategies 100
9.3 Advanced Electrospray Ionization Mass Spectrometry Instrumentation 102
9.4 Conclusion 105
References 105
10 Monitoring Quality of Critical Reagents Used in Ligand Binding Assays with Liquid Chromatography Mass Spectrometry (LC-MS) 107
Brian Geist, Adrienne Clements-Egan, and Tong-Yuan Yang
10.1 Introduction 107
10.2 Case Study Examples 114
10.3 Discussion 122
Acknowledgment 126
References 126
11 Application of Liquid Chromatography-High Resolution Mass Spectrometry in the Quantification of Intact Proteins in Biological Fluids 129
Stanley (Weihua) Zhang, Jonathan Crowther, and Wenying Jian
11.1 Introduction 129
11.2 Workflows for Quantification of Proteins Using Full-Scan LC-HRMS 131
11.3 Internal Standard Strategy 133
11.4 Calibration and Quality Control (QC) Sample Strategy 135
11.5 Common Issues in Quantification of Proteins Using LC-HRMS 135
11.6 Examples of LC-HRMS-Based Intact Protein Quantification 137
11.7 Conclusion and Future Perspectives 138
Acknowledgment 140
References 140
12 LC-MS/MS Bioanalytical Method Development Strategy for Therapeutic Monoclonal Antibodies in Preclinical Studies 145
Hongyan Li, Timothy Heath, and Christopher A. James
12.1 Introduction: LC-MS/MS Bioanalysis of Therapeutic Monoclonal Antibodies 145
12.2 Highlights of Recent Method Development Strategies 146
12.3 Case Studies of Preclinical Applications of LC-MS/MS for Monoclonal Antibody Bioanalysis 154
12.4 Conclusion and Future Perspectives 156
References 158
13 Generic Peptide Strategies for LC-MS/MS Bioanalysis of Human Monoclonal Antibody Drugs and Drug Candidates 161
Michael T. Furlong
13.1 Introduction 161
13.2 A Universal Peptide LC-MS/MS Assay for Bioanalysis of a Diversity of Human Monoclonal Antibodies and Fc Fusion Proteins in Animal Studies 161
13.3 An Improved "Dual" Universal Peptide LC-MS/MS Assay for Bioanalysis of Human mAb Drug Candidates in Animal Studies 165
13.4 Extending the Universal Peptide Assay Concept to Human mAb Bioanalysis in Human Studies 170
13.5 Internal Standard Options for Generic Peptide LC-MS/MS Assays 173
13.6 Sample Preparation Strategies for Generic Peptide LC-MS/MS Assays 175
13.7 Limitations of Generic Peptide LC-MS/MS Assays 177
13.8 Conclusion 178
Acknowledgments 178
References 178
14 Mass Spectrometry-Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development 183
Yongjun Xue, Priya Sriraman, Matthew V. Myers, Xiaomin Wang, Jian Chen, Brian Melo, Martha Vallejo, Stephen E. Maxwell, and Sekhar Surapaneni
14.1 Introduction 183
14.2 Mechanism of Action 183
14.3 Mass Spectrometry Measurement for DAR Distribution of Circulating ADCs 186
14.4 Total Antibody Quantitation by Ligand Binding or LC-MS/MS 189
14.5 Total Conjugated Drug Quantitation by Ligand Binding or LC-MS/MS 193
14.6 Catabolite Quantitation by LC-MS/MS 196
14.7 Preclinical and Clinical Pharmacokinetic Support 197
14.8 Conclusion and Future Perspectives 198
References 198
15 Sample Preparation Strategies for LC-MS Bioanalysis of Proteins 203
Long Yuan and Qin C. Ji
15.1 Introduction 203
15.2 Sample Preparation Strategies to Improve Assay Sensitivity 205
15.3 Sample Preparation Strategies to Differentiate Free, Total, and ADA-Bound Proteins 213
15.4 Sample Preparation Strategies to Overcome Interference from Antidrug Antibodies or Soluble Target 214
15.5 Protein Digestion Strategies 214
15.6. Conclusion 215
Acknowledgment 216
References 216
16 Characterization of Protein Therapeutics by Mass Spectrometry 221
Wei Wu, Hangtian Song, Thomas Slaney, Richard Ludwig, Li Tao, and Tapan Das
16.1 Introduction 221
16.2 Variants Associated with Cysteine/Disulfide Bonds in Protein Therapeutics 221
16.3 N-C-Terminal Variants 225
16.4 Glycation 226
16.5 Oxidation 226
16.6 Discoloration 228
16.7 Sequence Variants 230
16.8 Glycosylation 232
16.9 Conclusion 240
References 240
Index 251
Chapter 1
Contemporary Protein Analysis by Ion Mobility Mass Spectrometry
Johannes P.C. Vissers and James I. Langridge
Waters Corporation, Wilmslow, UK
1.1 Introduction
The use of ion mobility as an analytical technique to detect and separate biomolecules dates back to the break of the century with the application of the method for proteomics (Valentine et al. 2006; McLean et al. 2005; Gabryelski and Froese 2003), glycomics (Taraszka et al. 2001; Jin et al. 2005; Hoaglund et al. 1997), and metabolomics (Dwivedi et al. 2008). It is a technique that separates gas-phase ions based upon their mobility in a buffer gas. This separation is related to ion size, shape, as well as m/z, and charge. The basis for separation by traditional drift tube ion mobility at a low electric limit can be derived from the Mason-Schamp equation:
where K = drift velocity vd/electric field strength E, µ = reduced mass of the ion (neutral given by (mneutralmion)/(mneutral + mion), kB = Boltzmann constant, T = temperature, z = charge state of the analyte ion, e = charge on an electron, N = number density of the drift gas, and O = average collision cross section. The hyphenation of ion mobility spectrometry (IMS) with MS is often referred to as ion mobility-mass spectrometry (IM-MS). The most common mass analyzer coupled with IMS comprises a time-of-flight (TOF) instrument due to the inherent high sampling rate, although other mass detection systems have been described (Kanu et al. 2008). Four different methods of ion mobility separation are currently used in combination with MS, including drift-time ion mobility spectrometry (DTIMS), aspiration ion mobility spectrometry (AIMS), differential mobility spectrometry (DMS), also called field-asymmetric waveform ion mobility spectrometry (FAIMS), and traveling-wave ion mobility spectrometry (TWIMS). A description of these methods is beyond the scope of this chapter, particularly since they have been reviewed in great detail elsewhere (Kanu et al. 2008; Lanucara et al. 2014).
The innovative demonstration of protein conformer separation by means of IMS by Clemmer et al. 1995 has prompted instrumental IM-MS designs and the broader application of IMS as an analytical tool. The designs by Pringle et al. 2007 and Baker et al. 2007, both orthogonal acceleration time-of-flight (oa-TOF) based IM-MS platform, but utilizing different IMS geometries, have been commercialized and applied for numerous applications and include drug metabolism/metabolites (Dear et al. 2010), lipids (Kliman et al. 2011), trace impurities (Eckers et al. 2007), carbohydrates (Vakhrushev et al. 2008, Schenauer et al. 2009), macromolecular protein species and viruses (Ruotolo et al. 2005, Bereszczak et al. 2014), metal-based anticancer drugs (Williams et al. 2009), and PEGylated conjugates (Bagal et al. 2008). In this chapter, the application of IMS for the identification, quantification, and characterization of proteins is illustrated by application examples that demonstrate the benefits of integrating IMS into the analytical schema in terms of increased resolution and sensitivity, as well as those obtained from collision cross section measurements.
1.2 Traveling-Wave Ion Mobility Mass Spectrometry
The principle of TWIMS is briefly discussed as it forms the basis of subsequent sections. A schematic of the device is shown in Figure 1.1. Details can be found in the papers of Pringle et al. 2007 and Giles et al. 2004. Ions are formed by electrospray ionization (ESI) in the source and subsequently pass through a quadrupole for mass selection before injection into the ion mobility cell. Unlike our other instruments, which use a uniform electric field across the cell for ion mobility experiments, so-called drift tube IMS, this device uses traveling-wave (T-wave) technology. The T-wave cell consists of a stacked-ring radio frequency (RF) ion guide, which incorporates a repeating sequence of transient voltages applied to the ring electrodes. These voltage pulses result in a traveling electric field that propels ions through the background gas present in the mobility cell. The total time taken for an ion to drift through the cell depends on its mobility, as well as the wave period and height, and the gas pressure. Ions with high mobility are better able to keep up with traveling waves and are pushed more quickly through the cell. Ions with low mobility crest over the waves more often and have to wait for subsequent waves to push them forward, resulting in longer drift times. To measure an arrival time distribution (ATD), ions are gated into the mobility cell using an up-front stacked-ring RF device that traps ions before releasing them into the IMS cell. The oa-TOF pulses in an asynchronous manner, sending ions that have exited the mobility cell into the TOF mass analyzer and finally to the detector. The sum of all detected ions is the ion mobility chromatogram, or mobilogram. Selecting a peak in the ion mobility chromatogram displays the underlying TOF mass spectrum. Resolution enhancements to the device are recently described (Giles et al. 2011).
Figure 1.1 Triwave ion mobility optics detail comprising a trap, helium cell, ion mobility separator and transfer.
(Source: Williams et al. 2012. Reproduced with permission of GIT.)
1.3 IM-MS and LC-IM-MS Analysis of Simple and Complex Mixtures
1.3.1 Cross Section and Structure
By measuring the mobility of an ion, information about the rotationally averaged collision cross section, which is given by shape and size, can be determined. The relationship between the mobility of an ion and its collision cross section has been derived in detail using kinetic theory (Mason and McDaniel 1988). When all experimental IM parameter values are held constant, a dependence of the ion mobility constant results only from the average cross section with K ~ 1/O (1996; Bowers et al./>; Henderson et al. 1999; Verbeck et al. 2002), where K = drift velocity vd/electric field strength E and O = average collision cross section. A detailed description of kinetic theory is beyond the scope of this discussion. Ruotolo et al. 2005 were among the first describing the use of IM-MS to decipherer protein complex structure. The analysis of the Trp RNA-binding attenuation protein (TRAP) provided compelling evidence that many features of protein assemblies, including quaternary structure, can be preserved in the absence of solvent molecules. The researchers made use of TWIMS coupled to a modified TOF mass spectrometer to measure the CCS of four charge states of an 11-mer complex, demonstrating that the lowest charge state exhibited the largest CCS, with a value in close agreement to that estimated for a ring structure determined by X-ray crystallography. To investigate the sensitivity of the various conformers to changes in internal energy, they examined collision cross sections of the apo TRAP complex as a function of activation energy by manipulating their acceleration in the atmospheric pressure interface of the instrument, shown in Figure 1.2. The experiment illustrated that when an internal energy is imparted to 22+ ions, an expansion of the collapsed state occurred, while for 19+ ions they could partially drive the structural transitions observed for the ring structure as a function of protein charge state. IM-MS has proved to be extremely useful for the structural analysis of proteins and protein assemblies as illustrated in a number of recent reviews (Lanucara et al. 2014; Zhong et al. 2012; Uetrecht et al. 2010; Snijder and Heck 2014).
Figure 1.2 Ion mobility data for selected charge states of apo-TRAP (19+, 21+, and 22+) as a function of activation energy (175, 125, and 50 V) applied in the high-pressure, sampling cone region of the instrument. The light gray and dark gray dashed lines represent the collision cross sections for collapsed and ring structures. (
(Source: Ruotolo et al. 2005. Reproduced with permission of The American Association for the Advancement of Science.)
Collision cross section measurements and structure IM-MS experiments are not restricted to the analysis of large molecules but have been applied to other molecule classes and applications as well. For example, Valentine et al. 1999 used IMS to measure collision cross sections for 660 peptide ions generated by tryptic digestion proteins. Measured cross sections were compiled into a database that contains peptide molecular weight and sequence information and can be used to generate average intrinsic contributions to cross section for different amino acid residues. This was achieved by relating unknown contributions of individual residues to the sequences and cross sections of database peptides. Size parameters were combined with information about amino acid composition to calculate cross sections for database peptides. Figures 1.3(a) and (b) summarize the work showing cross sections as a function of molecular weight for the singly and doubly charged database peptides, respectively (Valentine et al. 1999). A strong correlation of increasing cross section with increasing molecular weight was observed, suggesting that (predicted) cross section can be used as an additional search parameter for peptide identification. A follow-up study proposed that the method that employs intrinsic amino acid size parameters to obtain ion mobility predictions can be used to rank candidate peptide ion...
System requirements
File format: ePUB
Copy protection: Adobe-DRM (Digital Rights Management)
System requirements:
- Computer (Windows; MacOS X; Linux): Install the free reader Adobe Digital Editions prior to download (see eBook Help).
- Tablet/smartphone (Android; iOS): Install the free app Adobe Digital Editions or the app PocketBook before downloading (see eBook Help).
- E-reader: Bookeen, Kobo, Pocketbook, Sony, Tolino and many more (not Kindle).
The file format ePub works well for novels and non-fiction books – i.e., „flowing” text without complex layout. On an e-reader or smartphone, line and page breaks automatically adjust to fit the small displays.
This eBook uses Adobe-DRM, a „hard” copy protection. If the necessary requirements are not met, unfortunately you will not be able to open the eBook. You will therefore need to prepare your reading hardware before downloading.
Please note: We strongly recommend that you authorise using your personal Adobe ID after installation of any reading software.
For more information, see our ebook Help page.